StudyFinder

MT2015-25: Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Recruiting

To evaluate 3 year progression free survival (PFS) rate of high-risk neuroblastoma patients after treatment with a tandem consolidation of Thiotepa/ Cyclophosphamide and PBSC rescue followed by Carboplatin/Etoposide/ Melphalan (CEM) and PBSC rescue, as compared to historical controls of a single CEM consolidation course with PBSC rescue.

I'm interested

This study is NOT accepting healthy volunteers
Inclusion Criteria:

• less than 30 years old when diagnosis of neuroblastoma is made
• no uncontrolled infection
• recovered from acute toxicities of last cycle of induction chemotherapy
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Biological: Autologous Stem Cell Infusion, Drug: Carboplatin, Drug: Cyclophosphamide, Drug: Etoposide, Biological: Granulocyte colony stimulating factor, Drug: Melphalan, Drug: Thiotepa

Cancer

Neuroblastoma

Holly Franceen - hfrancee@umn.edu
Ashish Gupta
PHASE2
1601M82901
16776
See this study on ClinicalTrials.gov

Back